剂量密度化疗在乳腺癌术后辅助化疗中的应用

Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer

目的 探讨剂量密度化疗在乳腺癌术后辅助化疗中应用的安全性与可行性。方法 回顾性分析114例因乳腺癌行剂量密度辅助化疗患者的临床资料。结果 114例乳腺癌患者接受了剂量密度辅助化疗，根据复发风险，其中43例接受PE方案（紫杉醇＋表阿霉素）化疗，8例接受TE方案（多烯紫杉醇＋表阿霉素）化疗，36例采用CEF方案（环磷酰胺＋表阿霉素＋5-Fu），27例采用EC方案（环磷酰胺＋表阿霉素）。除3例患者无法耐受外，其余111例患者均顺利完成所有治疗。Ⅲ度以上不良反应包括粒细胞缺乏（6．3％）、恶心和呕吐（11．7％）、周围神经改变（3．6％）。结论 乳腺癌术后辅助化疗采用剂量密度的方法是安全可行的，其远期疗效尚需进一步观察。

Objective To investigate the safety and feasibility of dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer. Methods The data of 114 breast cancer patients treated with adjuvant dose dense chemotherapy was retrospectively analyzed. Results 114 breast cancer patients received postoperative adjuvant dose dense chemotherapy from Jan. 2004 to March 2005. The patients were treated with different regimens according to their recurrence risk： 43 with paclitaxel ＋ epirubicin（PE）, 8 with taxotere ＋ epirubicin （TE）, 36 with cyclophosphamide ＋ epirubicin ＋ 5-Fu （CEF） and 27 with epirubicin ＋5-Fu（EC）. Totally, 111 patients except 3 completed the dose dense chemotherapy smoothly. Major toxicities severer than grade m included： neutropenia in 6.3% of the patients, nausea and vomit in 11.7%, peripheral neuropathy in 3.6%. Conclusion Postoperative adjuvant dose dense chemotherapy for breast cancer patient is feasible and safe, but the long-term outcome still needs further observation.